Getting Mounjaro for weight loss online starts with a telehealth consultation, but there’s an important distinction to understand first: Mounjaro is FDA-approved only for type 2 diabetes. The same active ingredient, tirzepatide, is sold under the brand name Zepbound for weight loss. Some providers prescribe Mounjaro off-label for weight management, while others will steer you toward Zepbound. Either way, the online process follows a similar path.
Mounjaro vs. Zepbound: What You’re Actually Getting
Mounjaro and Zepbound contain the identical active ingredient, tirzepatide. The difference is regulatory. The FDA approved Mounjaro for improving blood sugar in adults with type 2 diabetes, and later approved Zepbound specifically for chronic weight management. When a telehealth provider prescribes tirzepatide for weight loss, they may write a prescription for either brand depending on your medical profile, insurance coverage, and their clinical judgment.
Zepbound’s approval covers adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnea. These same thresholds are what most telehealth platforms use to determine eligibility regardless of which brand they prescribe.
Who Qualifies
To get a tirzepatide prescription online, you generally need to meet one of two criteria: a BMI of 30 or above, or a BMI of 27 or above combined with a weight-related health condition. Those conditions include type 2 diabetes, high blood pressure, abnormal cholesterol levels, obstructive sleep apnea, or cardiovascular disease.
Your provider will also review your medical history for contraindications. People with a personal or family history of certain thyroid cancers, for example, are not candidates. If you’re currently taking another GLP-1 medication, you cannot use tirzepatide at the same time.
How the Online Process Works
Most telehealth platforms follow a three-step process: intake, consultation, and delivery.
You start by filling out a medical questionnaire covering your weight, BMI, medical history, current medications, lifestyle habits, and previous weight loss attempts. Some platforms then connect you with a licensed provider through a video call, while others handle the entire evaluation through asynchronous messaging. On platforms like Hers, for instance, a provider reviews your submitted answers and communicates through a secure in-app messaging system without requiring a live call in most states.
Lab work requirements vary. Some telehealth services ask for bloodwork (either through an in-person lab visit or an at-home testing kit), while others are fully online. If your provider determines tirzepatide is appropriate, they write a prescription that either goes to your local pharmacy or ships directly to your door.
After you start the medication, most platforms offer ongoing provider access for dose adjustments, side effect management, and check-ins. Many include resources on injection technique, nutrition, and what to expect at each dose level.
Telehealth Platforms to Consider
Eli Lilly, the manufacturer of both Mounjaro and Zepbound, lists several independent telehealth providers on its website. These include Form Health, 9amHealth, and knownwell. Each offers personalized plans with licensed providers and can prescribe medication when appropriate.
Form Health is covered by many insurance plans including Medicare and offers a self-pay option. Its dietitians hold specialized obesity management certifications. 9amHealth supports Spanish-language care and offers at-home lab testing. knownwell covers the broadest insurance range, including some Medicaid plans, and has both virtual and in-person options.
These are far from the only choices. Hers, Ro, PlushCare, Calibrate, and other established telehealth companies also offer weight loss consultations that can result in tirzepatide prescriptions. When choosing a platform, look for one that uses licensed U.S. providers, offers ongoing medical support, and clearly explains its pricing before you commit.
What the Dosing Schedule Looks Like
Tirzepatide starts at 2.5 mg once weekly for the first four weeks. This introductory dose lets your body adjust and is not meant as a long-term maintenance dose. After four weeks, your provider increases the dose to 5 mg. From there, the dose can go up in 2.5 mg increments every four weeks or longer, depending on how you respond and tolerate side effects. The maximum dose is 15 mg per week.
This gradual ramp-up is important. Jumping to higher doses too quickly increases the risk of nausea, vomiting, and other gastrointestinal side effects. Your telehealth provider should be guiding each dose increase based on your progress and tolerance, not putting you on a fixed escalation schedule regardless of symptoms.
Cost and How to Lower It
The list price for Mounjaro is $1,112.16 for a one-month supply (four pens). What you actually pay depends heavily on your insurance plan.
Eli Lilly offers a Mounjaro Savings Card that can bring the cost down to as little as $25 for up to a three-month prescription for eligible patients. If your insurance doesn’t allow three-month fills, the savings card still works for one-month prescriptions at $25. Eligibility requirements apply, and uninsured patients may face different terms than those with commercial insurance.
If you have insurance, your plan may cover Zepbound for weight loss more readily than Mounjaro, since Zepbound carries the specific obesity indication. Some plans require prior authorization, step therapy (trying other treatments first), or only cover the medication at certain BMI thresholds. Your telehealth provider can often help navigate the authorization process.
Why You Should Avoid Compounded Versions
Searching for cheaper tirzepatide online will lead you to compounding pharmacies offering discount alternatives. The FDA has raised serious concerns about these products. As of July 2025, the agency had received 545 adverse event reports associated with compounded tirzepatide.
The problems are varied and alarming. Some compounded products have arrived warm or without adequate refrigeration, which degrades the medication. The FDA has identified fraudulent products with fake pharmacy names on the labels, where the compounding pharmacies listed either don’t exist or didn’t actually produce the medication. Dosing errors are a recurring issue: patients have injected incorrect amounts because compounded products use different concentrations than the brand-name versions, and even some healthcare providers have miscalculated doses.
There have also been reports of providers prescribing compounded tirzepatide at doses beyond what’s in the FDA-approved labeling, whether through larger single doses, more frequent injections, or faster dose escalation. Some compounders have sold salt forms of related medications that are chemically different from the approved drug, with unknown safety profiles. At least one adverse event involving a product labeled as compounded tirzepatide, from a pharmacy that didn’t actually compound it, resulted in injection site reactions including swelling, pain, and a red lump.
The FDA-approved versions of tirzepatide undergo rigorous manufacturing and quality review. Compounded versions do not. The cost savings are real, but so are the risks.